Request a Brochure

Learn, explore and unleash your inner chef.

For more information, contact:
Melini Hadjitheori
melinih@marcusveanscy.com

How can generic companies improve their internal capabilities to deal with multiple projects?

I believe that generic companies have to ruthlessly prioritize their internal resources to drive the most promising (valuable) projects, instead of trying to do too many things with too little resources. This activity requires a sound methodology with measurable criteria. Last but not least it is important, that top management understands and reviews the outcome of these regular exercises and approves them. At the end, fast decision making and implementation of the outcome is key to bring the results to life.

What is needed to ensure alignment between country and global portfolio levels?

From my experience it is of utmost importance, that colleagues from the HQ and country have a strong connection and good understanding of each other. Depending on the size and structure of the organization, several models exist. In the Sanofi Generics Franchise the Global functions communicate through regional platforms with countries. The regional platforms ensure a strong representation of the needs of the affiliates towards Global, while translating global initiatives and requests into tangible “portfolio tools” for the countries. Finally a clear understanding of roles and responsibilities is important to manage expectations as countries should remain empowered to drive their local product portfolio.

Why is it important to adopt a patient-centric approach?

Especially for Value-Added Medicines it is important to understand the unmet needs of patients. Examples in this area are new fixed dose combinations or easier to handle devices in respiratory. Sometimes already small improvements – e.g. better taste masking or more convenient packaging - can also improve patient’s life or at least their product experience. Overall it is clear, that such projects can only be developed in close exchange with patients and health care professionals.

What would you like to achieve by attending the Strategic Product and Portfolio Management for Generics?

As a speaker I am happy to share my experience and present the achievements of Zentiva/Sanofi Generics in the area of Value Added Medicines. As a participant I look forward to expanding my network and listening to ideas from others.

Ahead of the Strategic Product and Portfolio Management for Generics conference, we spoke with Dr. Tassilo Krug v. Nidda, Strategic Portfolio and Licensing Director Europe for Sanofi Generics. The interview sheds light onto the internal capabilities of Generic companies for dealing with multiple projects; for aligning country and global portfolio levels and adopting a patient-centric approach.

About the conference:

This marcus evans conference will look at the new developments in the portfolio management strategies, based on innovation, efficiency and diversification. On the background of all that changes, companies are pushed to redefine their internal strategy and organization to be able to perform in different markets and adapt with agility to rapid changes and new opportunities. Having a right pricing strategy, being able to align local and global expectations, preparing for product launches will be part of the event’s fundamentals. It will also focus on promising area for growth such as value-added generics or biosimilars, as well as new developments in partnership and acquisitions to improve presence in large and segmented markets. The Strategic Product and Portfolio Management for Generics conference, will take place from the 19th to 21st September 2016 in the Le Palais Art Hotel Prague, Czech Republic.

About the speaker:

Dr. Tassilo Krug v. Nidda is the Strategic Portfolio and Licensing Director Europe for Sanofi Generics, based in Prague. Previously, he has worked at Sandoz, part of Novartis, as Head of Global Portfolio Management. He started his career in the Generic industry in 2004 as a Portfolio Manager in the HQ of ratiopharm. Tassilo holds a Ph.D. in Biochemistry and worked for the Boston Consulting Group as an Associate Consultant in Frankfurt/Germany.

Entering Into Value-Added Generics Potential

An interview with Sanofi

Dr. Tassilo Krug v. Nidda, Strategic Portfolio and Licensing Director Europe for Sanofi Generics, based in Prague